Page header

Opinion of the Transparency Council – posaconazole

At its meeting on 10 March 2025, the Transparency Council adopted opinion No. 40/2025 on the reimbursement of medicinal products containing the active substance posaconazole for indications, doses or administration methods that differ from those specified in the Summary of Product Characteristics

 

Publication of the opinion >>